Key result
Renal denervation did not reduce office systolic blood pressure at 6 months compared to a sham procedure in patients with resistant hypertension.
Why the study?
Does renal sympathetic denervation improve outcomes in patients with resistant hypertension?
Does renal sympathetic denervation improve outcomes in patients with resistant hypertension?
This review highlights the neutral results of the SYMPLICITY HTN-3 trial, questioning the efficacy of renal denervation for resistant hypertension.
Answers are grounded in this paper and cite their sources.
Renal denervation should not yet change practice in resistant hypertension; leaves open questions about refined techniques or subgroups for future trials.
Resistant hypertension is, by definition, a challenge to most physicians treating hypertension. Renal sympathetic denervation has shown promising early results in treating this condition. The SYMPLICITY HTN-3 is the most recent trial to report the effects of this technique on resistant hypertension. This review discusses this study and its surprising neutral results before ending with an overview of key lessons learned.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2014) conducted a review in Resistant hypertension (n=535). Renal denervation vs. Sham procedure (renal angiography) was evaluated on Change in office systolic blood pressure at 6 months (MD -2.39, p=0.26). Renal denervation did not reduce office systolic blood pressure at 6 months compared to a sham procedure in patients with resistant hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: